TrialWorld journal of gastroenterology2024

Inetetamab combined with S-1 and oxaliplatin as first-line treatment for human epidermal growth factor receptor 2-positive gastric cancer.

Ying Kong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.